MPR Weekly Dose cover art

MPR Weekly Dose

MPR Weekly Dose

Written by: MPR Weekly Dose
Listen for free

Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.All rights reserved Hygiene & Healthy Living
Episodes
  • MPR Weekly Dose Podcast #290 — Weltruza, Hovilpri Approved, Atezolizuman Regimens for Stage III dMMR Colon CA; Subcutaneous Tx for TED; Vanda’s Anxiety Tx Falls

    MPR Weekly Dose Podcast #290 — Weltruza, Hovilpri Approved, Atezolizuman Regimens for Stage III dMMR Colon CA; Subcutaneous Tx for TED; Vanda’s Anxiety Tx Falls
    Oct 16 2026
    Recent regulatory and clinical developments include the approval of Weltruza — the first once-monthly subcutaneous long-acting formulation of olanzapine for schizophrenia — as well as the first subcutaneous therapy for thyroid eye disease and Hovilpri for refractory mucocutaneous HSV. In addition, the FDA expanded Tecentriq’s reach with newly approved regimens, while Vanda Pharmaceuticals reported disappointing trial results for its social anxiety disorder candidate. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    14 mins
  • MPR Weekly Dose Podcast #289 — Juvmo for Parkinson Disease; Camzyos Approval Expanded; MS Treatment Gains Priority Review; Sudden BLA Withdrawal for a Key Lung Cancer Candidate

    MPR Weekly Dose Podcast #289 — Juvmo for Parkinson Disease; Camzyos Approval Expanded; MS Treatment Gains Priority Review; Sudden BLA Withdrawal for a Key Lung Cancer Candidate
    Oct 2 2026
    New FDA approvals for Juvmo in Parkinson disease and Camzyos in pediatric obstructive hypertrophic cardiomyopathy, a Priority Review green light for fenebrutinib in MS, and the sudden BLA withdrawal for a key lung cancer candidate. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    12 mins
  • MPR Weekly Dose Podcast #285 — Mounjaro Approval Expanded; Updated RSV Pediatric Recs; Remibrutinib Shows Promise for Relapsing MS; Boxed Warning Added to Injectafer PI

    MPR Weekly Dose Podcast #285 — Mounjaro Approval Expanded; Updated RSV Pediatric Recs; Remibrutinib Shows Promise for Relapsing MS; Boxed Warning Added to Injectafer PI
    Sep 4 2026

    Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in relapsing MS; and The FDA adds a boxed warning to Injectafer.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    11 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet